Nabriva Therapeutics AG (NASDAQ:NBRV) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a note issued to investors on Saturday.

According to Zacks, “Nabriva Therapeutics AG is a biopharmaceutical company. The Company is involved in the research and development of novel anti-infective agents to treat serious infections, which focus on the pleuromutilin class of antibiotics. Its product candidate consists of BC-3781, developed for the treatment of serious skin infections and bacterial pneumonia caused by MRSA and other drug resistant bacteria; BC-7013, a topical pleuromutilin antibiotic which are in different clinical trial. Nabriva Therapeutics AG is based in Vienna, Austria. “

NBRV has been the subject of several other research reports. SunTrust Banks, Inc. began coverage on Nabriva Therapeutics AG in a research note on Friday, August 25th. They issued a “buy” rating and a $20.00 target price for the company. Cantor Fitzgerald restated a “buy” rating and issued a $16.00 target price on shares of Nabriva Therapeutics AG in a research note on Friday, September 1st. HC Wainwright raised their target price on Nabriva Therapeutics AG from $18.00 to $20.00 and gave the stock a “buy” rating in a research note on Wednesday. Needham & Company LLC restated a “buy” rating and issued a $18.00 target price (up previously from $15.00) on shares of Nabriva Therapeutics AG in a research note on Tuesday, September 19th. Finally, ValuEngine downgraded Nabriva Therapeutics AG from a “hold” rating to a “sell” rating in a research note on Tuesday, August 1st. One research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have given a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $19.03.

Nabriva Therapeutics AG (NBRV) traded up $0.39 during mid-day trading on Friday, hitting $6.14. The stock had a trading volume of 361,540 shares, compared to its average volume of 530,633. Nabriva Therapeutics AG has a 12 month low of $3.52 and a 12 month high of $14.10.

Nabriva Therapeutics AG (NASDAQ:NBRV) last issued its earnings results on Monday, August 7th. The biotechnology company reported ($0.54) EPS for the quarter, topping the consensus estimate of ($5.83) by $5.29. The company had revenue of $1.05 million during the quarter, compared to the consensus estimate of $1.34 million. research analysts forecast that Nabriva Therapeutics AG will post -2.35 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Zacks Investment Research Lowers Nabriva Therapeutics AG (NBRV) to Hold” was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark law. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2017/11/04/zacks-investment-research-lowers-nabriva-therapeutics-ag-nbrv-to-hold.html.

In other news, major shareholder Hbm Healthcare Investments (Ca sold 17,790 shares of Nabriva Therapeutics AG stock in a transaction dated Monday, August 7th. The stock was sold at an average price of $10.50, for a total transaction of $186,795.00. Following the completion of the sale, the insider now owns 2,373,387 shares in the company, valued at approximately $24,920,563.50. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, major shareholder Vivo Capital Viii, Llc purchased 52,631 shares of the company’s stock in a transaction dated Monday, September 18th. The shares were acquired at an average price of $9.46 per share, with a total value of $497,889.26. The disclosure for this purchase can be found here. In the last quarter, insiders have bought 57,219 shares of company stock valued at $535,919 and have sold 74,840 shares valued at $714,161. Company insiders own 2.75% of the company’s stock.

Several institutional investors and hedge funds have recently modified their holdings of the company. Almanack Investment Partners LLC. boosted its position in shares of Nabriva Therapeutics AG by 482.2% during the 2nd quarter. Almanack Investment Partners LLC. now owns 907,183 shares of the biotechnology company’s stock valued at $1,633,000 after acquiring an additional 751,366 shares during the last quarter. Nationwide Fund Advisors boosted its position in shares of Nabriva Therapeutics AG by 4.6% during the 2nd quarter. Nationwide Fund Advisors now owns 180,924 shares of the biotechnology company’s stock valued at $2,032,000 after acquiring an additional 7,924 shares during the last quarter. Finally, Royal Bank of Canada raised its holdings in shares of Nabriva Therapeutics AG by 19.6% during the 2nd quarter. Royal Bank of Canada now owns 52,807 shares of the biotechnology company’s stock valued at $553,000 after buying an additional 8,650 shares in the last quarter. Hedge funds and other institutional investors own 50.24% of the company’s stock.

Nabriva Therapeutics AG Company Profile

Nabriva Therapeutics plc is a clinical stage biopharmaceutical company. The Company is engaged in engaged in the research and development of novel anti-infectives to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The Company’s medicinal chemistry has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations of its lead product candidate, lefamulin.

Get a free copy of the Zacks research report on Nabriva Therapeutics AG (NBRV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Nabriva Therapeutics AG (NASDAQ:NBRV)

Receive News & Ratings for Nabriva Therapeutics AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics AG and related companies with MarketBeat.com's FREE daily email newsletter.